DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Ovarian Serous Adenofibroma — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOvarian Serous Adenofibroma maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ovarian serous adenofibroma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
KRas proto-oncogene, GTPase (KRAS) — KRAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gnpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7VVB · 1.7 Å · ligand PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER (GNP). Experimental structure, not a prediction.
What the evidence adds up to
Ovarian serous adenofibroma is not directly described in the provided abstracts. The 2025 literature review states that endometrioid adenofibromas are uncommon benign ovarian tumours, accounting for approximately 1% of epithelial neoplasms, and are predominantly unilateral. A 2014 case report describes a 36-year-old woman with a mucinous cystadenofibroma, a benign cystic mass, who successfully underwent a left oophorectomy. A 2023 report on tubal adenofibroma notes that adenofibroma is an uncommon tumour containing both epithelial and stromal components, and describes a "black-sponge" appearance on MR imaging that may support the diagnosis, though no current evidence allows diagnosis by imaging alone.
A 1995 case report describes a 66-year-old woman with ovarian serous adenocarcinoma that produced alpha-fetoprotein (AFP) during chemotherapy, with 57% of serum AFP binding Con A and 43% not, similar to gastrointestinal and yolk-sac tumours. This abstract concerns malignant transformation, not adenofibroma, and provides no data on survival, response rates, or sample sizes beyond the single patient. No abstract reports treatment outcomes, response rates, or survival figures for any adenofibroma subtype.
The 2025 review highlights diagnostic challenges, the role of immunohistochemistry, and the need for careful surgical and fertility-preserving strategies, noting possible risks linked to fertility treatments. For early-stage, small, non-invasive tumours, laparoscopy is the preferred approach. The 2014 and 2023 cases report successful surgery without complications. No abstract provides evidence for drug repurposing, and no drug is mentioned in any abstract.
What is still missing: prospective studies with adequate sample sizes, standardised diagnostic criteria for serous adenofibroma specifically, any clinical trial testing a drug for this tumour type, and data on long-term outcomes beyond single case reports. Patient stratification by histological subtype and imaging characteristics remains unaddressed.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Case Reports in Obstetrics and Gynecology · 2014 · 15 citations · open access
A Case of Mucinous Cystadenofibroma of the Ovary
AbstractOvarian adenofibroma is a rare benign tumour originating from the germinal lining and stroma of the ovary. We describe here the case of a 36-year-old woman with an ovarian mucinous cystadenofibroma that was diagnosed as a benign cystic mass of the ovary before surgery. The tumour was a cystic lesion composed of 2 regions: one filled with mucinous fluid and the other with yellowish solid components. The patient successfully underwent a left oophorectomy.
Romanian Journal of Morphology and Embryology · 2025 · 11 citations · open access
Endometrioid adenofibroma of ovary – a literature review
AbstractBACKGROUND/OBJECTIVES: Ovarian neoplasms are the third most common gynecological cancer and carry a poorer prognosis than breast cancer. Endometrioid borderline ovarian tumors (EBOTs) are intermediate epithelial lesions, histologically showing glandular patterns with mild to moderate atypia and no stromal invasion. Study selection for review: A comprehensive electronic search was conducted on PubMed to identify risk factors and etiological determinants associated with ovarian endometrioid adenofibroma (EA). CASE PRESENTATION: A 27-year-old woman with a left ovarian cyst underwent a laparoscopic procedure to remove the adnexa after imaging showed a 6 cm mass. Surgery was successful, and she was discharged without complications. CONCLUSIONS: This study highlights the diagnostic challenges of EBOTs, the essential role of immunohistochemistry, and the need for careful surgical and fertility-preserving strategies. It also draws attention to possible risks linked to fertility treatments. Fertility preservation is crucial in young patients, favoring uterine and ovarian conservation. In early-stage, small, non-invasive tumors, laparoscopy is the preferred approach. EAs are uncommon benign ovarian tumors, accounting for approximately 1% of epithelial neoplasms, and are predominantly unilateral.
Journal of Obstetrics and Gynaecology · 1995 · 5 citations
A Case of Ovarian Serous Adenocarcinoma Suggestive of Transformation to an AFP‐Producing Tumor during Chemotherapy
AbstractOvarian serous adenocarcinoma with AFP production is very rare. A case involving a 66-year-old woman with an elevated serum AFP level without detectable hepatic involvement. AFP-positive cells were seen in the tumor at the second surgery. Fifty-seven percent of serum AFP from the patient bound Con A, whereas 43% did not. Similarly, 54% of the tumor fluid also bound Con A. These suggest that the serum AFP was similar to that of gastrointestinal tumors and yolk-sac tumors.
Journal of Ankara University Faculty of Medicine · 2023 · 0 citations · open access
Ultrasonography and MR Imaging Findings in a Patient with Tubal Adenofibroma
AbstractAdenofibroma is an uncommon tumor containing both epithelial and stromal components.In this report, we aimed to present a case of fallopian tube adenofibroma with an emphasis on imaging findings.On ultrasonography, a spongy semisolid mass, and on T2-weighted MR sequences, a multilocular hyperintense mass adjacent to normal left ovary were seen.Tiny hyperintense locules were noted in the hypointense fibrous component, which resembles the "black-sponge" appearance previously described for ovarian adenofibromas.Although there is no current evidence that the diagnosis of tubal adenofibroma can solely be made by imaging, the presence of "black sponge"-like appearance may support this diagnosis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
